BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 17654686)

  • 21. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fluorescence in situ hybridization identifies complex chromosomal aberrations in multiple myeloma].
    Liu SY; Huang JW; Zhang J; Du HP; Jiang H; Li JY; Xue YQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Dec; 24(6):685-8. PubMed ID: 18067084
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21.
    Tomlinson GE; Douglass EC; Pollock BH; Finegold MJ; Schneider NR
    Genes Chromosomes Cancer; 2005 Oct; 44(2):177-84. PubMed ID: 15981236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Frequency and prognostic value of chromosome abnormalities in multiple myeloma].
    Kurahashi S; Sawamoto A; Sugimoto T; Narimatsu H; Iwasaki T; Adachi T; Suzuki H; Hayakawa F; Sugiura I
    Rinsho Ketsueki; 2007 Nov; 48(11):1455-61. PubMed ID: 18080502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrent chromosomal abnormalities in lymphomas in fine needle aspirates of lymph node.
    Trcić RL; Sustercić D; Kuspilić M; Jelić-Puskarić B; Fabijanić I; Kardum-Skelin I
    Coll Antropol; 2010 Jun; 34(2):387-93. PubMed ID: 20698107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonrandom chromosome abnormalities in lymphoma.
    Bloomfield CD; Arthur DC; Frizzera G; Levine EG; Peterson BA; Gajl-Peczalska KJ
    Cancer Res; 1983 Jun; 43(6):2975-84. PubMed ID: 6850608
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetics and molecular cytogenetics in multiple myeloma.
    Liebisch P; Döhner H
    Eur J Cancer; 2006 Jul; 42(11):1520-9. PubMed ID: 16781866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Karyotypic characterization of urinary bladder transitional cell carcinomas.
    Fadl-Elmula I; Gorunova L; Mandahl N; Elfving P; Lundgren R; Mitelman F; Heim S
    Genes Chromosomes Cancer; 2000 Nov; 29(3):256-65. PubMed ID: 10992300
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytogenetic profile of childhood acute lymphoblastic leukemia in Oman.
    Udayakumar AM; Bashir WA; Pathare AV; Wali YA; Zacharia M; Khan AA; Soliman H; Al-Lamki Z; Raeburn JA
    Arch Med Res; 2007 Apr; 38(3):305-12. PubMed ID: 17350480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential analysis of chromosome aberrations in multiple myeloma during disease progression.
    Wu KL; Beverloo B; Velthuizen SJ; Sonneveld P
    Clin Lymphoma Myeloma; 2007 Jan; 7(4):280-5. PubMed ID: 17324335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytogenetic data as a prognostic factor in multiple myeloma patients: involvement of 1p12 region an adverse prognostic factor.
    Panani AD; Ferti AD; Papaxoinis C; Raptis SA; Roussos Ch
    Anticancer Res; 2004; 24(6):4141-6. PubMed ID: 15736465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined spectral karyotyping, comparative genomic hybridization, and in vitro apoptyping of a panel of Burkitt's lymphoma-derived B cell lines reveals an unexpected complexity of chromosomal aberrations and a recurrence of specific abnormalities in chemoresistant cell lines.
    Karpova MB; Schoumans J; Blennow E; Ernberg I; Henter JI; Smirnov AF; Nordenskjöld M; Fadeel B
    Int J Oncol; 2006 Mar; 28(3):605-17. PubMed ID: 16465364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia.
    Taniwaki M; Nishida K; Takashima T; Nakagawa H; Fujii H; Tamaki T; Shimazaki C; Horiike S; Misawa S; Abe T
    Blood; 1994 Oct; 84(7):2283-90. PubMed ID: 7919347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.
    Calasanz MJ; Cigudosa JC; Odero MD; Ferreira C; Ardanaz MT; Fraile A; Carrasco JL; Solé F; Cuesta B; Gullón A
    Genes Chromosomes Cancer; 1997 Feb; 18(2):84-93. PubMed ID: 9115968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.
    Aydin C; Ulas T; Hangul C; Yucel OK; Iltar U; Salim O; Ekinci D; Berker Karauzum S
    Indian J Hematol Blood Transfus; 2020 Apr; 36(2):284-291. PubMed ID: 32425379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of recurrent chromosomal breakpoints in multiple myeloma with complex karyotypes by combined G-banding, spectral karyotyping, and fluorescence in situ hybridization analyses.
    Sáez B; Martín-Subero JI; Largo C; Martín MC; Odero MD; Prosper F; Siebert R; Calasanz MJ; Cigudosa JC
    Cancer Genet Cytogenet; 2006 Sep; 169(2):143-9. PubMed ID: 16938572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetic and FISH analysis of 93 multiple myeloma Moroccan patients.
    Hamdaoui H; Benlarroubia O; Ait Boujmia OK; Mossafa H; Ouldim K; Belkhayat A; Smyej I; Benrahma H; Dehbi H; Chegdani F
    Mol Genet Genomic Med; 2020 Sep; 8(9):e1363. PubMed ID: 32573970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Duplication of chromosome arms 9q and 11q: evidence for a novel, 14q32 translocation-independent pathogenetic pathway in multiple myeloma.
    Liebisch P; Scheck D; Erné SA; Wellmann A; Wendl C; Janczik S; Kolmus S; Kröber A; Einsele H; Straka C; Goldschmidt H; Benner A; Stilgenbauer S; Döhner H
    Genes Chromosomes Cancer; 2005 Jan; 42(1):78-81. PubMed ID: 15390182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.